TC BioPharm is a clinical-stage cell therapy company that develops novel immunotherapies based on a proprietary allogeneic (donor-derived) gamma-delta T cell platform. Its cell-based pipeline is being developed to treat a range of diseases, including cancer and severe viral infections. The company is advancing its platform toward new therapeutic candidates built on these allogeneic gamma-delta T cells. TC BioPharm is currently in the clinical stage, indicating active clinical development programs. Financially, the company recently secured a strategic investment of $3.5 million. The reporting article attributes the information to IT桔子 and does not provide further operational or financial metrics.

Total raised

$4M

Funding rounds

1

Latest round

Equity

Latest activity

Dec 2023